Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and Pan-PPAR partial agonists

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Liberato, Marcelo Vizoná ^a   Nascimento, Alessandro S ^a   Ayers, Steven D ^b   Lin, Jean Z ^b   Cvoro, Aleksandra ^b   Silveira, Rodrigo L ^e   Martínez, Leandro ^e   Souza, Paulo C T ^e   Saidemberg, Daniel ^c   Deng, Tuo ^b   Amato, Angela Angelica ^d   Togashi, Marie ^d   Hsueh, Willa A ^b   Phillips, Kevin ^b   Palma, Mário Sérgio ^c   Neves, Francisco A R ^d   Skaf, Munir S ^e   Webb, Paul ^b   Polikarpov, Igor ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d UNIVERSITY OF BRASILIA   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLIN DEPENDENT KINASE 5; MEDIUM CHAIN FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; AZO COMPOUND; FATTY ACID; OIL RED O; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; FATTY ACID ANALYSIS; IN VITRO STUDY; INSULIN RESISTANCE; LIGAND BINDING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR BLOCKING; STRUCTURE ANALYSIS; ANIMAL; CELL STRAIN 3T3; CHEMISTRY; CRYSTALLIZATION; DRUG POTENTIATION; HELA CELL; HUMAN; METABOLISM; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

BACTERIA (MICROORGANISMS);

3T3 CELLS; ANIMALS; AZO COMPOUNDS; CRYSTALLIZATION; FATTY ACIDS; HELA CELLS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PPAR GAMMA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; THIAZOLIDINEDIONES;

EID: 84861381281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036297     Document Type: Article

References (44)

1. Willson TM, Lambert MH, Kliewer SA, (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70: 341-367.
2. Evans RM, Barish GD, Wang YX, (2004) PPARs and the complex journey to obesity. Nat Med 10: 355-361.
3. Tontonoz P, Spiegelman BM, (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77: 289-312.
4. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, et al. (2008) Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15: 924-931.
5. Li Y, Zhang J, Schopfer FJ, Martynowski D, Garcia-Barrio MT, et al. (2008) Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol 15: 865-867.
6. Rangwala SM, Lazar MA, (2002) The dawn of the SPPARMs? Sci STKE 2002 pe9.
7. Cock TA, Houten SM, Auwerx J, (2004) Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 5: 142-147.
8. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 17: 662-676.
9. Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, et al. (2006) A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20: 809-830.
10. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466: 451-456.
11. Nettles KW, Greene GL, (2005) Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol 67: 309-333.
12. Glass CK, Rosenfeld MG, (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141.
13. Kliewer SA, Xu HE, Lambert MH, Willson TM, (2001) Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56: 239-263.
14. Xu HE, Li Y, (2008) Ligand-dependent and-independent regulation of PPAR gamma and orphan nuclear receptors. Sci Signal 1: pe52.
15. Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, et al. (2007) Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15: 1258-1271.
16. Waku T, Shiraki T, Oyama T, Morikawa K, (2009) Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands. FEBS Lett 583: 320-324.
17. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, et al. (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477-481.
18. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395: 137-143.
19. Malapaka RR, Khoo SK, Zhang J, Choi JH, Zhou XE, et al. (2011) Identification and mechanism of a ten carbon fatty acid as a modulating ligand of peroxisome proliferator activated receptors. J Biol Chem 287: 183: 195.
20. Karplus M, McCammon JA, (2002) Molecular dynamics simulations of biomolecules. Nat Struct Biol 9: 646-652.
21. Niesen FH, Berglund H, Vedadi M, (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2: 2212-2221.
22. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94: 4318-4323.
23. Yang JY, Della-Fera MA, Rayalam S, Park HJ, Ambati S, et al. (2009) Regulation of adipogenesis by medium-chain fatty acids in the absence of hormonal cocktail. J Nutr Biochem 20: 537-543.
24. Kallenberger BC, Love JD, Chatterjee VK, Schwabe JW, (2003) A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat Struct Biol 10: 136-140.
25. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, et al. (2008) Structure of the intact PPAR-gamma-RXR nuclear receptor complex on DNA. Nature 456: 350-356.
26. Martinez L, Nascimento AS, Nunes FM, Phillips K, Aparicio R, et al. (2009) Gaining ligand selectivity in thyroid hormone receptors via entropy. Proc Natl Acad Sci U S A 106: 20717-20722.
27. Nagao K, Yanagita T, (2010) Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res 61: 208-212.
28. Han J, Hamilton JA, Kirkland JL, Corkey BE, Guo W, (2003) Medium-chain oil reduces fat mass and down-regulates expression of adipogenic genes in rats. Obes Res 11: 734-744.
29. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, et al. (2009) Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138: 476-488.
30. Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, et al. (2006) Reevaluation of the PPAR-beta/delta ligand binding domain model reveals why it exhibits the activated form. Mol Cell 21: 1-2.
31. Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, et al. (2006) Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. J Mol Biol 356: 1005-1013.
32. Krylova IN, Sablin EP, Moore J, Xu RX, Waitt GM, et al. (2005) Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell 120: 343-355.
33. Sablin EP, Blind RD, Krylova IN, Ingraham JG, Cai F, et al. (2009) Structure of SF-1 bound by different phospholipids: evidence for regulatory ligands. Mol Endocrinol 23: 25-34.
34. Wisely GB, Miller AB, Davis RG, Thornquest AD Jr, Johnson R, et al. (2002) Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 10: 1225-1234.
35. Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, et al. (2007) Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem 282: 18625-18633.
36. Guimaraes BG, Sanfelici L, Neuenschwander RT, Rodrigues F, Grizolli WC, et al. (2009) The MX2 macromolecular crystallography beamline: a wiggler X-ray source at the LNLS. J Synchrotron Radiat 16: 69-75.
37. Minor W, Tomchick D, Otwinowski Z, (2000) Strategies for macromolecular synchrotron crystallography. Structure 8: R105-110.
38. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
39. Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, et al. (2005) Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. J Med Chem 48: 4457-4468.
40. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
41. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
42. Martinez L, Andreani R, Martinez JM, (2007) Convergent algorithms for protein structural alignment. BMC Bioinformatics 8: 306.
43. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 27-38.
44. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.